Sperm from donor with cancer-causing gene was used to conceive almost 200 children

An anonymous donor whose sperm contained a mosaic TP53 mutation that causes Li‑Fraumeni syndrome has fathered at least 197 children across Europe via the European Sperm Bank, with some children already diagnosed with cancer and several deaths reported; up to 20% of the donor's sperm carried the mutation, which if transmitted results in a lifetime cancer risk as high as ~90%. The donor supplied clinics for about 17 years from 2005 and his samples were used by 67 fertility clinics in 14 countries (not sold to UK clinics, though a very small number of British patients were treated in Denmark), prompting the bank to block the donor and acknowledge that national donor‑use limits were breached in some markets (Belgium, for example, produced 53 children from one donor where the national cap is six families). The case underscores material regulatory, legal and reputational risks for large cross‑border sperm banks and national regulators, is likely to accelerate calls for tighter international limits and oversight (even as experts warn genetic screening cannot catch every rare mosaic mutation), and could raise compliance costs and constrain supply in an industry already dependent on large international providers.

Analysis

A sperm donor with a mosaic TP53 mutation associated with Li-Fraumeni syndrome has fathered at least 197 children via the European Sperm Bank across 67 clinics in 14 countries over roughly 17 years; up to 20% of his sperm reportedly carried the mutation and inherited cases carry up to an ~90% lifetime cancer risk, with multiple children already diagnosed and several deaths reported. The bank says it blocked the donor once discovered and acknowledged donor-use limits were breached in some jurisdictions (Belgium produced 53 children from one donor where the national cap is six); the samples were not sold to UK clinics but a very small number of British patients were treated in Denmark and notified. Experts in the article note mosaic mutations can evade routine screening and attribute part of the problem to dependence on large international donor banks and inconsistent national limits, while professional bodies have proposed limits (ESHRE suggested 50 families) but warned this would not eliminate rare genetic risks. The episode creates concentrated regulatory, legal and reputational risk for cross-border sperm banks and fertility clinics, is likely to accelerate tighter oversight and compliance costs, and could constrain donor supply or shift demand toward clinics with stronger traceability and domestic sourcing, producing sector-specific operational and financial stress despite only modest immediate market-wide impact.

Key Decisions for Investors

• Reassess direct or indirect exposure to large cross-border sperm banks and pure-play donor-bank businesses and consider reducing position size or applying a valuation haircut until regulatory and liability outcomes are clearer
• Monitor regulatory developments in Denmark, Belgium, the UK and ESHRE policy proposals (including family-cap debates) as potential catalysts for fines, litigation and higher compliance costs that would pressure margins
• Prefer investments in fertility clinics or healthcare providers that demonstrate robust donor traceability, domestic sourcing and stronger clinical governance as likely beneficiaries if cross-border supply tightens
• Limit exposure to companies concentrated in donor distribution and consider hedging tools or position caps given elevated reputational and long-tail clinical liability risk
• Track patient notification outcomes and any announced compensation or monitoring programs, as these will inform the scale of future cash outflows and operational burdens for implicated providers